Francisco J. Esteva: The importance of improving ctDNA methodologies
Francisco J. Esteva, Chief, Division of Hematology and Medical Oncology at Lenox Hill Hospital shared a post on LinkedIn:
“Finding circulating tumor DNA, or ctDNA using a blood test is strongly tied to the survival outcomes of patients with metastatic breast cancer, MBC.
A thorough review and meta-analysis of 37 studies, which included 4,264 patients, showed that using standardized methods in ctDNA studies is vital for producing reliable results. This research points out that consistent cell-free DNA extraction techniques are essential for achieving robust and reproducible findings.
While ctDNA provides important prognostic information, it doesn’t predict what treatments will be effective for individual patients in their MBC journey.
This study underscores the importance of improving ctDNA methodologies. These advancements could lead to more informed treatment decisions and better patient outcomes in MBC.”
Source: Francisco J. Esteva/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023